Dennis H. Kim
Toronto, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.
Journal: JCO oncology practice
Published: June 29, 2026
Blood-based epigenetic instability linked to human aging and disease.
Journal: Nature communications
Published: June 18, 2025
Prolonged length of stay in high-risk patients undergoing allogeneic stem cell transplantation: a call to action for addressing healthcare challenges.
Journal: Bone marrow transplantation
Published: January 05, 2025
A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes.
Journal: Hematology/oncology and stem cell therapy
Published: August 01, 2022
The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia.
Journal: EJHaem
Published: February 07, 2022
Outcomes of Patients Diagnosed With Chronic Lymphocytic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results From a Tertiary Care Center.
Journal: Hematology/oncology and stem cell therapy
Published: April 21, 2021
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
Journal: British journal of haematology
Published: January 21, 2021
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.
Journal: Bone marrow transplantation
Published: April 14, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026